Skip to main content
SpringerLink
Log in

Functional Implications of Genetic Polymorphisms in the Multidrug Resistance Gene MDR1 (ABCB1)

  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

The multidrug resistance (MDR1) gene product P-glycoprotein is a membrane protein that functions as an ATP-dependent efflux pump, transporting exogenous and endogenous substrates from the inside of cells to the outside. Physiological expression of P-glycoprotein in tissues with excretory or protective function is a major determinant of drug disposition and provides a cellular defense mechanism against potentially harmful compounds. Therefore, P-glycoprotein has significant impact on therapeutic efficacy and toxicity as it plays a key role in absorption of oral medications from the intestinal tract, excretion into bile and urine, and distribution into protected tissues such as the brain and testes. There is increasing interest in the possible role of genetic variation in MDR1 in drug therapy. Numerous genetic polymorphisms in MDR1 have been described, some of which have been shown to determine P-glycoprotein expression levels and substrate transport. Furthermore, some of these polymorphisms have an impact on pharmacokinetic and pharmacodynamic profiles of drug substrates and directly influence outcome and prognosis of certain diseases. This review will focus on the impact of genetic variation in MDR1 on expression and function of P-glycoprotein and the implications of this variation for drug therapy and disease risk.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. C. J. Chen, D. Clark, K. Ueda, I. Pastan, M. M. Gottesman, and I. B. Roninson. Genomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoproteins. J. Biol. Chem. 265:506-514 (1990).

    Google Scholar 

  2. J. E. Chin, R. Soffir, K. E. Noonan, K. Choi, and I. B. Roninson. Structure and expression of the human MDR (P-glycoprotein) gene family. Mol. Cell. Biol. 9:3808-3820 (1989).

    Google Scholar 

  3. A. Fojo, R. Lebo, N. Shimizu, J. E. Chin, I. B. Roninson, G. T. Merlino, M. M. Gottesman, and I. Pastan. Localization of multidrug resistance-associated DNA sequences to human chromosome 7. Somat. Cell Mol. Genet. 12:415-420 (1986).

    Google Scholar 

  4. T. W. Loo and D. M. Clarke. The transmembrane domains of the human multidrug resistance P-glycoprotein are sufficient to mediate drug binding and trafficking to the cell surface. J. Biol. Chem. 274:24759-24765 (1999).

    Google Scholar 

  5. B. Greiner, M. Eichelbaum, P. Fritz, H. P. Kreichgauer, O. von Richter, J. Zundler, and H. K. Kroemer. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest. 104:147-153 (1999).

    Google Scholar 

  6. R. B. Kim, M. F. Fromm, C. Wandel, B. Leake, A. J. Wood, D. M. Roden, and G. R. Wilkinson. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101:289-294 (1998).

    Google Scholar 

  7. A. H. Schinkel, C. A. Mol, E. Wagenaar, L. van Deemter, J. J. Smit, and P. Borst. Multidrug resistance and the role of P-glycoprotein knockout mice. Eur. J. Cancer 31A:1295-1298 (1995).

    Google Scholar 

  8. A. H. Schinkel, E. Wagenaar, C. A. Mol, and L. van Deemter. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 97:2517-2524 (1996).

    Google Scholar 

  9. C. J. Chen, J. E. Chin, K. Ueda, D. P. Clark, I. Pastan, M. M. Gottesman, and I. B. Roninson. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47:381-389 (1986).

    Google Scholar 

  10. M. M. Baekelandt, R. Holm, J. M. Nesland, C. G. Trope, and G. B. Kristensen. P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer. Anticancer Res. 20:1061-1067 (2000).

    Google Scholar 

  11. I. O. Ng, C. L. Liu, S. T. Fan, and M. Ng. Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response. Am. J. Clin. Pathol. 113:355-363 (2000).

    Google Scholar 

  12. C. Wuchter, K. Leonid, V. Ruppert, M. Schrappe, T. Buchner, C. Schoch, T. Haferlach, J. Harbott, R. Ratei, B. Dorken, and W. D. Ludwig. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. Haematologica 85:711-721 (2000).

    Google Scholar 

  13. M. M. Gottesman, I. Pastan, and S. V. Ambudkar. P-glycoprotein and multidrug resistance. Curr. Opin. Genet. Dev. 6:610-617 (1996).

    Google Scholar 

  14. A. H. Schinkel, E. Wagenaar, L. van Deemter, C. A. Mol, and P. Borst. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Invest. 96:1698-1705 (1995).

    Google Scholar 

  15. A. Seelig, X. L. Blatter, and F. Wohnsland. Substrate recognition by P-glycoprotein and the multidrug resistance-associated protein MRP1: a comparison. Int. J. Clin. Pharmacol. Ther. 38:111-121 (2000).

    Google Scholar 

  16. R. B. Kim, C. Wandel, B. Leake, M. Cvetkovic, M. F. Fromm, P. J. Dempsey, M. M. Roden, F. Belas, A. K. Chaudhary, D. M. Roden, A. J. Wood, and G. R. Wilkinson. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm. Res. 16:408-414 (1999).

    Google Scholar 

  17. L. Becquemont, C. Verstuyft, R. Kerb, U. Brinkmann, M. Lebot, P. Jaillon, and C. Funck-Brentano. Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin. Pharmacol. Ther. 70:311-316 (2001).

    Google Scholar 

  18. D. Durr, B. Stieger, G. A. Kullak-Ublick, K. M. Rentsch, H. C. Steinert, P. J. Meier, and K. Fattinger. St John’s Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin. Pharmacol. Ther. 68:598-604 (2000).

    Google Scholar 

  19. N. Kioka, J. Tsubota, Y. Kakehi, T. Komano, M. M. Gottesman, I. Pastan, and K. Ueda. P-glycoprotein gene (MDR1) cDNA from human adrenal: normal P-glycoprotein carries Gly185 with an altered pattern of multidrug resistance. Biochem. Biophys. Res. Commun. 162:224-231 (1989).

    Google Scholar 

  20. L. A. Mickley, J. S. Lee, Z. Weng, Z. Zhan, M. Alvarez, W. Wilson, S. E. Bates, and T. Fojo. Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors. Blood 91:1749-1756 (1998).

    Google Scholar 

  21. R. B. Kim, B. F. Leake, E. F. Choo, G. K. Dresser, S. V. Kubba, U. I. Schwarz, A. Taylor, H. G. Xie, J. McKinsey, S. Zhou, L. B. Lan, J. D. Schuetz, E. G. Schuetz, and G. R. Wilkinson. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. 70:189-199 (2001).

    Google Scholar 

  22. D. L. Kroetz, C. Pauli-Magnus, L. M. Hodges, C. C. Huang, M. Kawamoto, S. J. Johns, D. Stryke, T. E. Ferrin, J. DeYoung, T. Taylor, E. J. Carlson, I. Herskowitz, K. M. Giacomini, and A. G. Clark. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 13:481-494 (2003).

    Google Scholar 

  23. S. Saito, A. Iida, A. Sekine, Y. Miura, C. Ogawa, S. Kawauchi, S. Higuchi, and Y. Nakamura. Three hundred twenty-six genetic variations in genes encoding nine members of ATP-binding cassette, subfamily B (ABCB/MDR/TAP), in the Japanese population. J. Hum. Genet. 47:38-50 (2002).

    Google Scholar 

  24. M. Tanabe, I. Ieiri, N. Nagata, K. Inoue, S. Ito, Y. Kanamori, M. Takahashi, Y. Kurata, J. Kigawa, S. Higuchi, N. Terakawa, and K. Otsubo. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J. Pharmacol. Exp. Ther. 297:1137-1143 (2001).

    Google Scholar 

  25. S. Hoffmeyer, O. Burk, O. von Richter, H. P. Arnold, J. Brockmoller, A. Johne, I. Cascorbi, T. Gerloff, I. Roots, M. Eichelbaum, and U. Brinkmann. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA 97:3473-3478 (2000).

    Google Scholar 

  26. S. Ito, I. Ieiri, M. Tanabe, A. Suzuki, S. Higuchi, and K. Otsubo. Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics 11:175-184 (2001).

    Google Scholar 

  27. I. Cascorbi, T. Gerloff, A. Johne, C. Meisel, S. Hoffmeyer, M. Schwab, E. Schaeffeler, M. Eichelbaum, U. Brinkmann, and I. Roots. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin. Pharmacol. Ther. 69:169-174 (2001).

    Google Scholar 

  28. K. Tang, S. M. Ngoi, P. C. Gwee, J. M. Chua, E. J. Lee, S. S. Chong, and C. G. Lee. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 12:437-450 (2002).

    Google Scholar 

  29. A. G. Clark, K. M. Weiss, D. A. Nickerson, S. L. Taylor, A. Buchanan, J. Stengard, V. Salomaa, E. Vartiainen, M. Perola, E. Boerwinkle, and C. F. Sing. Haplotype structure and population genetic inferences from nucleotide-sequence variation in human lipoprotein lipase. Am. J. Hum. Genet. 63:595-612 (1998).

    Google Scholar 

  30. M. Stephens, N. J. Smith, and P. Donnelly. A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 68:978-989 (2001).

    Google Scholar 

  31. G. Chen, G. E. Duran, K. A. Steger, N. J. Lacayo, J. P. Jaffrezou, C. Dumontet, and B. I. Sikic. Multidrug-resistant human sarcoma cells with a wmutant P-glycoprotein, altered phenotype, and resistance to cyclosporins. J. Biol. Chem. 272:5974-5982 (1997).

    Google Scholar 

  32. S. V. Ambudkar, S. Dey, C. A. Hrycyna, M. Ramachandra, I. Pastan, and M. M. Gottesman. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 39:361-398 (1999).

    Google Scholar 

  33. T. Hoof, A. Demmer, M. R. Hadam, J. R. Riordan, and B. Tummler. Cystic fibrosis-type mutational analysis in the ATP-binding cassette transporter signature of human P-glycoprotein MDR1. J. Biol. Chem. 269:20575-20583 (1994).

    Google Scholar 

  34. C. Kimchi-Sarfaty, J. J. Gribar, and M. M. Gottesman. Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol. Pharmacol. 62:1-6 (2002).

    Google Scholar 

  35. N. Morita, T. Yasumori, and K. Nakayama. Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities. Biochem. Pharmacol. 65:1843-1852 (2003).

    Google Scholar 

  36. M. Hitzl, S. Drescher, H. van der Kuip, E. Schaffeler, J. Fischer, M. Schwab, M. Eichelbaum, and M. F. Fromm. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 11:293-298 (2001).

    Google Scholar 

  37. K. Oselin, T. Gerloff, P. M. Mrozikiewicz, R. Pahkla, and I. Roots. MDR1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes. Fundam. Clin. Pharmacol. 17:463-469 (2003).

    Google Scholar 

  38. A. Johne, K. Kopke, T. Gerloff, I. Mai, S. Rietbrock, C. Meisel, S. Hoffmeyer, R. Kerb, M. F. Fromm, U. Brinkmann, M. Eichelbaum, J. Brockmoller, I. Cascorbi, and I. Roots. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin. Pharmacol. Ther. 72:584-594 (2002).

    Google Scholar 

  39. Y. Kurata, I. Ieiri, M. Kimura, T. Morita, S. Irie, A. Urae, S. Ohdo, H. Ohtani, Y. Sawada, S. Higuchi, and K. Otsubo. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin. Pharmacol. Ther. 72:209-219 (2002).

    Google Scholar 

  40. T. Sakaeda, T. Nakamura, M. Horinouchi, M. Kakumoto, N. Ohmoto, T. Sakai, Y. Morita, T. Tamura, N. Aoyama, M. Hirai, M. Kasuga, and K. Okumura. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm. Res. 18:1400-1404 (2001).

    Google Scholar 

  41. M. Horinouchi, T. Sakaeda, T. Nakamura, Y. Morita, T. Tamura, N. Aoyama, M. Kasuga, and K. Okumura. Significant genetic linkage of MDR1 polymorphisms at positions 3435 and 2677: functional relevance to pharmacokinetics of digoxin. Pharm. Res. 19:1581-1585 (2002).

    Google Scholar 

  42. T. Gerloff, M. Schaefer, A. Johne, K. Oselin, C. Meisel, I. Cascorbi, and I. Roots. MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. Br. J. Clin. Pharmacol. 54:610-616 (2002).

    Google Scholar 

  43. S. Drescher, E. Schaeffeler, M. Hitzl, U. Hofmann, M. Schwab, U. Brinkmann, M. Eichelbaum, and M. F. Fromm. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br. J. Clin. Pharmacol. 53:526-534 (2002).

    Google Scholar 

  44. D. Anglicheau, C. Verstuyft, P. Laurent Puig, L. Becquemont, M. H. Schlageter, B. Cassinat, P. Beaune, C. Legendre, and E. Thervet. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J. Am. Soc. Nephrol. 14:1889-1896 (2003).

    Google Scholar 

  45. C. R. Yates, W. Zhang, P. Song, S. Li, A. O. Gaber, M. Kotb, M. R. Honaker, R. R. Alloway, and B. Meibohm. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J. Clin. Pharmacol. 43:555-564 (2003).

    Google Scholar 

  46. I. A. Macphee, S. Fredericks, T. Tai, P. Syrris, N. D. Carter, A. Johnston, L. Goldberg, and D. W. Holt. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 74:1486-1489 (2002).

    Google Scholar 

  47. H. Zheng, S. Webber, A. Zeevi, E. Schuetz, J. Zhang, P. Bowman, G. Boyle, Y. Law, S. Miller, J. Lamba, and G. J. Burckart. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am. J. Transplant. 3:477-483 (2003).

    Google Scholar 

  48. N. von Ahsen, M. Richter, C. Grupp, B. Ringe, M. Oellerich, and V. W. Armstrong. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin. Chem. 47:1048-1052 (2001).

    Google Scholar 

  49. D. A. Hesselink, H. Ngyuen, M. Wabbijn, P. J. Gregoor, E. W. Steyerberg, I. C. Van Riemsdijk, W. Weimar, and T. Van Gelder. Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids. Br. J. Clin. Pharmacol. 56:327-330 (2003).

    Google Scholar 

  50. J. Fellay, C. Marzolini, E. R. Meaden, D. J. Back, T. Buclin, J. P. Chave, L. A. Decosterd, H. Furrer, M. Opravil, G. Pantaleo, D. Retelska, L. Ruiz, A. H. Schinkel, P. Vernazza, C. B. Eap, and A. Telenti. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 359:30-36 (2002).

    Google Scholar 

  51. W. Siegmund, K. Ludwig, T. Giessmann, P. Dazert, E. Schroeder, B. Sperker, R. Warzok, H. K. Kroemer, and I. Cascorbi. The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin. Pharmacol. Ther. 72:572-583 (2002).

    Google Scholar 

  52. J. F. Watchko, M. J. Daood, and T. W. Hansen. Brain bilirubin content is increased in P-glycoprotein-deficient transgenic null mutant mice. Pediatr. Res. 44:763-766 (1998).

    Google Scholar 

  53. L. F. Marques-Santos, R. R. Bernardo, E. F. de Paula, and V. M. Rumjanek. Cyclosporin A and trifluoperazine, two resistance-modulating agents, increase ivermectin neurotoxicity in mice. Pharmacol. Toxicol. 84:125-129 (1999).

    Google Scholar 

  54. R. L. Roberts, P. R. Joyce, R. T. Mulder, E. J. Begg, and M. A. Kennedy. A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics J. 2:191-196 (2002).

    Google Scholar 

  55. A. Yamauchi, I. Ieiri, Y. Kataoka, M. Tanabe, T. Nishizaki, R. Oishi, S. Higuchi, K. Otsubo, and K. Sugimachi. Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation 74:571-572 (2002).

    Google Scholar 

  56. A. J. Sadeque, C. Wandel, H. He, S. Shah, and A. J. Wood. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin. Pharmacol. Ther. 68:231-237 (2000).

    Google Scholar 

  57. C. Pauli-Magnus, J. Feiner, C. Brett, E. Lin, and D. L. Kroetz. No effect of MDR1 C3435T polymorphisms on disposition and brain entry of loperamide. Clin Pharm Ther 74:487-498 (2003).

    Google Scholar 

  58. T. Furuno, M. T. Landi, M. Ceroni, N. Caporaso, I. Bernucci, G. Nappi, E. Martignoni, E. Schaeffeler, M. Eichelbaum, M. Schwab, and U. M. Zanger. Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson’s disease. Pharmacogenetics 12:529-534 (2002).

    Google Scholar 

  59. M. Drozdzik, M. Bialecka, K. Mysliwiec, K. Honczarenko, J. Stankiewicz, and Z. Sych. Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson’s disease. Pharmacogenetics 13:259-263 (2003).

    Google Scholar 

  60. A. Siddiqui, R. Kerb, M. E. Weale, U. Brinkmann, A. Smith, D. B. Goldstein, N. W. Wood, and S. M. Sisodiya. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N. Engl. J. Med. 348:1442-1448 (2003).

    Google Scholar 

  61. M. Schwab, E. Schaeffeler, C. Marx, M. F. Fromm, B. Kaskas, J. Metzler, E. Stange, H. Herfarth, J. Schoelmerich, M. Gregor, S. Walker, I. Cascorbi, I. Roots, U. Brinkmann, U. M. Zanger, and M. Eichelbaum. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology 124:26-33 (2003).

    Google Scholar 

  62. M. Siegsmund, U. Brinkmann, E. Schaffeler, G. Weirich, M. Schwab, M. Eichelbaum, P. Fritz, O. Burk, J. Decker, P. Alken, U. Rothenpieler, R. Kerb, S. Hoffmeyer, and H. Brauch. Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors. J. Am. Soc. Nephrol. 13:1847-1854 (2002).

    Google Scholar 

  63. M. M. van den Heuvel-Eibrink, E. A. Wiemer, M. J. de Boevere, B. van der Holt, P. J. Vossebeld, R. Pieters, and P. Sonneveld. MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia. Blood 97:3605-3611 (2001).

    Google Scholar 

  64. T. Illmer, U. S. Schuler, C. Thiede, U. I. Schwarz, R. B. Kim, S. Gotthard, D. Freund, U. Schakel, G. Ehninger, and M. Schaich. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res. 62:4955-4962 (2002).

    Google Scholar 

  65. A. Kafka, G. Sauer, C. Jaeger, R. Grundmann, R. Kreienberg, R. Zeillinger, and H. Deissler. Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int. J. Oncol. 22:1117-1121 (2003).

    Google Scholar 

  66. I. Ifergan, N. F. Bernard, J. Bruneau, M. Alary, C. M. Tsoukas, and M. Roger. Allele frequency of three functionally active polymorphisms of the MDR-1 gene in high-risk HIV-negative and HIV-positive Caucasians. AIDS 16:2340-2342 (2002).

    Google Scholar 

  67. Z. L. Brumme, W. W. Dong, K. J. Chan, R. S. Hogg, J. S. Montaner, M. V. O’Shaughnessy, and P. R. Harrigan. Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response. AIDS 17:201-208 (2003).

    Google Scholar 

  68. M. Nasi, V. Borghi, M. Pinti, C. Bellodi, E. Lugli, S. Maffei, L. Troiano, L. Richeldi, C. Mussini, R. Esposito, and A. Cossarizza. MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients. AIDS 17:1696-1698 (2003).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Clinical Pharmacology, Department of Internal Medicine, University Hospital Zurich, Zurich, Switzerland

    Christiane Pauli-Magnus

  2. Department of Biopharmaceutical Sciences, School of Pharmacy, University of California San Francisco, San Francisco, California, USA

    Deanna L. Kroetz

Authors
  1. Christiane Pauli-Magnus
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Deanna L. Kroetz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christiane Pauli-Magnus.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pauli-Magnus, C., Kroetz, D.L. Functional Implications of Genetic Polymorphisms in the Multidrug Resistance Gene MDR1 (ABCB1) . Pharm Res 21, 904–913 (2004). https://doi.org/10.1023/B:PHAM.0000029276.21063.0b

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:PHAM.0000029276.21063.0b

Search

Navigation